Other Income & Expense

Foreign Currency Transaction Gain (Loss), Pre-tax

Vertex Pharmaceuticals Foreign Currency Transaction Gain (Loss), Pre-tax remained flat by 0.0% to -$3.43M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 49.8%, from -$6.83M to -$3.43M. Over 2 years (FY 2023 to FY 2025), Foreign Currency Transaction Gain (Loss), Pre-tax shows an upward trend with a -25.4% CAGR.

Analysis

StatementIncome Statement
SectionOther Income & Expense
First reportedQ1 2023
Last reportedQ4 2025Feb 13, 2026
Metric ID: glw_foreign_currency_transaction_gain_loss_pretax

Historical Data

3 years
 FY'23FY'24FY'25
Value-$24.60M-$27.30M-$13.70M
YoY Change—-11.0%+49.8%
Range-$27.30M – -$13.70M
CAGR-25.4%
Avg YoY Growth+19.4%
Median YoY Growth+19.4%

Frequently Asked Questions

What is Vertex Pharmaceuticals's foreign currency transaction gain (loss), pre-tax?
Vertex Pharmaceuticals (VRTX) reported foreign currency transaction gain (loss), pre-tax of -$3.43M in Q4 2025.
How has Vertex Pharmaceuticals's foreign currency transaction gain (loss), pre-tax changed year-over-year?
Vertex Pharmaceuticals's foreign currency transaction gain (loss), pre-tax increased by 49.8% year-over-year, from -$6.83M to -$3.43M.
What is the long-term trend for Vertex Pharmaceuticals's foreign currency transaction gain (loss), pre-tax?
Over 2 years (2023 to 2025), Vertex Pharmaceuticals's foreign currency transaction gain (loss), pre-tax has grown at a -25.4% compound annual growth rate (CAGR), from -$24.60M to -$13.70M.